Preliminary 48-week Safety and Efficacy Data of VIR-2218 Alone and in Combination With Pegylated Interferon Alfa in Participants With Chronic HBV Infection

Conference Reports for NATAP

The Liver Meeting
Digital Experience
AASLD
Washington on 04-08
November 2022


Preliminary 48-week Safety and Efficacy Data of VIR-2218 Alone and in Combination With Pegylated Interferon Alfa in Participants With Chronic HBV Infection

	AASLD 4-8 November 2022; Washington, DC